Y. Douglas Dolginow
Keine laufenden Positionen mehr
Profil
Y.
Douglas Dolginow is the founder of Veracyte, Inc. (founded in 2006).
He held former positions as Director at Xceed Molecular Corp., President & Chief Operating Officer at Oncormed, Inc., and Executive Vice President at Gene Logic, Inc. He also worked as a Faculty Member at The University of California, San Francisco.
Dolginow received his undergraduate degree from Harvard University and his doctorate from the University of Kansas.
Ehemalige bekannte Positionen von Y. Douglas Dolginow
| Unternehmen | Position | Ende |
|---|---|---|
Gene Logic, Inc.
 Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Corporate Officer/Principal | 03.01.2008 |
| The University of California, San Francisco | Corporate Officer/Principal | - |
| VERACYTE, INC. | Gründer | - |
Oncormed, Inc.
 Oncormed, Inc. Medical SpecialtiesHealth Technology Oncormed, Inc., is a genomics services company that characterizes newly discovered genes to establish their medical relevance and provides molecular profiling of patients for pharmacogenomic and therapeutic purposes. The company's mission is to accelerate the translation of cancer related genetic discoveries into clinically useful products and services through strategic collaborations with pharmaceutical, genomic and biotechnology companies. | Präsident | - |
Xceed Molecular Corp.
 Xceed Molecular Corp. Medical SpecialtiesHealth Technology Xceed Molecular Corporation is a molecular diagnostic company dedicated to commercializing a platform for automated gene expression analysis and developing proprietary clinical research assays and custom arrays. They develop tools and content aimed at accelerating the current market trend towards 'translational medicine', and bridging the gap from gene signature validation to clinical diagnostics. The Ziplex Automated Workstation is the first integrated and fully automated hybridization system for multiplex gene expression signatures. Their integrated solution - the Ziplex System - features this innovative instrument platform and focused-content TipChip arrays and reagents to perform highly multiplexed molecular assays with superior accuracy, reproducibility, speed and scalability. The Ziplex System is designed to provide the ease-of-use in assay automation and analytics that is required to successfully translate gene expression analysis from research use into routine practice. Xceed complements the Ziplex platform by offering Gene Expression Services and Assay Development Services. | Direktor/Vorstandsmitglied | - |
Ausbildung von Y. Douglas Dolginow
| Harvard University | Undergraduate Degree |
| University of Kansas | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VERACYTE, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Health Technology |
Xceed Molecular Corp.
Xceed Molecular Corp. Medical SpecialtiesHealth Technology Xceed Molecular Corporation is a molecular diagnostic company dedicated to commercializing a platform for automated gene expression analysis and developing proprietary clinical research assays and custom arrays. They develop tools and content aimed at accelerating the current market trend towards 'translational medicine', and bridging the gap from gene signature validation to clinical diagnostics. The Ziplex Automated Workstation is the first integrated and fully automated hybridization system for multiplex gene expression signatures. Their integrated solution - the Ziplex System - features this innovative instrument platform and focused-content TipChip arrays and reagents to perform highly multiplexed molecular assays with superior accuracy, reproducibility, speed and scalability. The Ziplex System is designed to provide the ease-of-use in assay automation and analytics that is required to successfully translate gene expression analysis from research use into routine practice. Xceed complements the Ziplex platform by offering Gene Expression Services and Assay Development Services. | Health Technology |
Oncormed, Inc.
Oncormed, Inc. Medical SpecialtiesHealth Technology Oncormed, Inc., is a genomics services company that characterizes newly discovered genes to establish their medical relevance and provides molecular profiling of patients for pharmacogenomic and therapeutic purposes. The company's mission is to accelerate the translation of cancer related genetic discoveries into clinically useful products and services through strategic collaborations with pharmaceutical, genomic and biotechnology companies. | Health Technology |
